The Institute for Clinical and Economic Review (ICER) announced Thursday, April 11, that it will review the comparative clinical effectiveness and value of several treatments for type 2 diabetes. According to a press release, ICER will assess Novo Nordisk's oral semaglutide and compare it to Novo […]
Latest Stories
Sanofi Unveils Subscription Program for Insulin
Drugmaker Sanofi has revealed a new subscription-like model for its insulin treatment, according to a FiercePharma report, and is charging $99/month to receive the drug. According to the report, Sanofi through its program is offering patients 10 boxes of insulin pens and 10 mL vials each […]
PBMs Point Fingers at Pharma for High Prices
Representatives from the top pharmacy benefit managers looked to shift blame off itself for high drug prices onto pharmaceutical companies during a Senate Finance Committee hearing on Tuesday, CNBC reports. Five executives representing CVS Health, Cigna, Prime Therapeutics, Human and […]
Sweetenham Spotlights Possible Benefits, Problems with RWE in Oncology
John Sweetenham, senior director of clinical affairs and executive medical director of Huntsman Cancer Institute at The University of Utah, in a recent write up takes a look at some of the potential benefits real-world evidence (RWE) has to offer in oncology, as well as some of the possible […]
Broadcasting, Advertising Groups Oppose Rule on Drug Prices in Ads
Bringing a new swath of opposition to the Trump administration's rule requiring drugmakers to include drug prices in their commercials, broadcasting and advertising groups say the rules could put a significant dent in a key revenue stream, The Hill reports. The Association of National Advertisers […]
Hospitals, Insurers Eye Drug Rebate Rule
Insurers and hospitals say the Centers for Medicare and Medicaid Services (CMS) should include in a recently-proposed rule some new requirements for pharmaceutical companies, Modern Healthcare reports. Organizations in response to the rule suggested that eliminating safe harbor for Medicare Part D […]
TEDMED 2020 Slated to Kick Off March 2
TEDMED 2020 is set for March 2-4 in Boston, the TEDMED team announced this week, with early-bird registration slated to open May 15. TEDMED in an email said it was "excited to bring our diverse, multi-disciplinary community Boston." "TEDMED is dedicated to inspiring change in health and medicine, […]
ICER Releases Report on Peanut Allergy Treatments
The Institute for Clinical and Economic Review on Tuesday, April 9, released a draft evidence report on the clinical effectiveness and value of DBV Technologies' Viaskin Peanut and Aimmune Therapeutics' AR101 for inducing immune tolerance to peanuts. The report will be open to public comment until […]
PBMs Testify Before Senate Finance Committee
Pharmacy benefit managers mostly dodged questions from policymakers during a Senate Finance Committee hearing Tuesday, STAT reports. However, Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) floated the possibility of legislative action. "Ranking member Wyden and I are committed to working on […]
PhRMA Responds to OIG’s Rebate Proposal
PhRMA on Monday, April 8, submitted comments on the Department of Health and Human Services Office of Inspector General's proposed rule for addressing the current rebate system. The rule, "Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe […]
